Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant FEC followed by docetaxel versus FEC followed by gemcitabine + docetaxel in primary invasive breast cancer
2007-001094-29Phase 3Completed
- Sponsor
- LMU Klinikum
- Start
- Dec 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, gemcitabine, epirubicin, fluorouracil, cyclophosphamide in breast cancer, sponsored by LMU Klinikum. Started Dec 2007; status: completed.
02
Drugs
docetaxelgemcitabineepirubicinfluorouracilcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-001094-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001094-29.